Using wearable and mobile data to diagnose and monitor movement disorders
The goal of the study is to use data from a smartphone to differentiate diseases and measure symptom severity.
ClinicalTrials.gov Link: clinicaltrials.gov/ct2/show/NCT04231487
About the Study
Eligible Ataxia Types
Spinocerebellar Ataxias
Type of Study
Research Study
Clinical Trial Phase
N/A
Age Range
Adult 18+
Study Start Date
11/01/2018
Estimated Completion Date
11/01/2023
IRB Approval #
Pro2018002015
Location(s)
Rutgers University
65 Bergen Street
Newark, NJ
Contact Information
Jean-Francois Daneault
jf.daneault@rutgers.edu
Phone: 973-972-8482
What does participation in the study entail?
Participation entails coming to the laboratory located in Newark NJ, for one session lasting about 1 hour. Some people may be asked to use the smartphone app at home, once a week, for 8 weeks.
What are the potential benefits for participants?
Participants will not benefit directly from the study. They will help us develop a tool that may become available to individuals with ataxia to improve their diagnosis and long-term management.
What are the potential risks for participants?
The risks are no greater than doing regular activities during daily life, such as walking.
Is there financial compensation?
Yes. $40.
Is there travel reimbursement?
No.
Who is eligible?
Adults with a diagnosis of spinocerebellar ataxia and that have been on a stable dose of medication for at least 30 days are eligible. People with severe cognitive impairment that limit their understanding of simple instructions, that have a diagnosis of another neurological condition, and that have severe mobility impairments due to other conditions, such as arthritis, are not eligible.
View Other Research Opportunities
Remote Assessment of Cognition, Affect, and Motor Function in Ataxias
This study aims to better understand how different brain and body functions (movement, speech, thinking skills, and mood) are affected in spinocerebellar ataxias, and how these functions change over the Read More…
Understanding the Spectrum of SCA1, SCA2, SCA3, SCA6 Through the Eyes of Patients and Caregivers
Biohaven Pharmaceuticals is now enrolling patients and spouses/parent/caregiver in a research study of patients and families affected by SCA. The study is regarding the burden of SCA types 1, 2, Read More…
The role of the cerebellum in movement and thought
Our research focuses on how people produce coordinated movement and coordinated thought, and how these abilities may be impacted by cerebellar degeneration. Link to Enroll: https://tinyurl.com/53ycmrcu About the Study Eligible Read More…
